Infugen Pharma Private Limited

Infugen Pharma Private Limited, established on February 4, 1999, in Sangli, Maharashtra, India, is a privately held pharmaceutical company specializing in the export of finished pharmaceutical formulations. The company operates under the Corporate Identification Number (CIN) U24231PN1999PTC013295 and is registered with the Registrar of Companies, Pune. Initially known as Jeshika Pharma Private Limited, it rebranded to Infugen Pharma Private Limited to better reflect its global aspirations. The authorized capital stands at ₹3 million, with a paid-up capital of ₹1 million. The company's registered office is located at Yashokamalharbhat Road, Opposite Sangli Urban Co-Op Bank Ltd, Sangli, Maharashtra, 416416.

Infugen Pharma has experienced significant growth since its inception, becoming one of the fastest-growing export houses in the healthcare sector. With over 30 years of experience, the company has expanded its product portfolio to include more than 100 products, available in over 25 countries. The company's focus on contract manufacturing services has enabled it to establish a strong presence in various international markets, including North and East Africa, French West Africa, Southeast Asia, Central America, the Caribbean, and CIS countries.

Infugen Pharma operates a WHO GMP-certified oncology unit with a production capacity of 500,000 tablets, 1 million capsules, and 200,000 veterinary tablets per shift. This facility underscores the company's commitment to maintaining high-quality standards in pharmaceutical manufacturing. Additionally, Infugen collaborates with other specialized formulation manufacturing units to enhance its product offerings and ensure compliance with global quality standards.

The leadership team at Infugen Pharma Private Limited includes:

• Sandeep Jagjeevan Modi: Director

• Bharat Jagjivan Bhate: Director

Both directors have been with the company since its inception on February 4, 1999. Their leadership has been instrumental in steering the company towards its current position in the pharmaceutical export sector.

Infugen Pharma has made significant strides in obtaining regulatory approvals across various international markets. The company holds WHO GMP certification for its oncology unit, ensuring compliance with international manufacturing standards. Infugen has also secured product registrations in multiple countries, including Nigeria, Tanzania, Kenya, Ghana, Uganda, the Philippines, Ethiopia, Zambia, Lesotho, Sri Lanka, the Democratic Republic of Congo, Vietnam, Ivory Coast, Cambodia, Portugal, Brazil, Tajikistan, and Yemen. These approvals facilitate the company's market access in the United States, European Union, United Kingdom, Australia, and Japan, enabling it to export its pharmaceutical formulations to these regions.

Infugen Pharma has strategically expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's product registrations in countries such as Nigeria, Tanzania, Kenya, Ghana, Uganda, the Philippines, Ethiopia, Zambia, Lesotho, Sri Lanka, the Democratic Republic of Congo, Vietnam, Ivory Coast, Cambodia, Portugal, Brazil, Tajikistan, and Yemen have facilitated its market penetration in these regions. The WHO GMP certification for its oncology unit further enhances the company's credibility and facilitates access to these markets.

Infugen Pharma's geographic strategy demonstrates a strong diversification approach, mitigating concentration risk by establishing a presence in multiple international markets. The company's product registrations across various countries in Africa, Latin America, and Southeast Asia reflect a strategic direction aimed at global expansion. This diversification not only broadens the company's market reach but also positions it to leverage growth opportunities in emerging economies. The focus on obtaining WHO GMP certification for its oncology unit underscores Infugen's commitment to meeting international quality standards, thereby enhancing its competitive edge in diverse markets.

As of March 2026, there is no publicly available information indicating that Infugen Pharma Private Limited has FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or a history of FDA inspections. The company's primary focus appears to be on markets outside the United States, as evidenced by its product registrations in countries such as Nigeria, Tanzania, Kenya, Ghana, Uganda, the Philippines, Ethiopia, Zambia, Lesotho, Sri Lanka, the Democratic Republic of Congo, Vietnam, Ivory Coast, Cambodia, Portugal, Brazil, Tajikistan, and Yemen.

Infugen Pharma's oncology unit has been accredited with WHO GMP certification, ensuring compliance with international manufacturing standards. This certification enhances the company's credibility and facilitates access to global markets. However, there is no publicly available information indicating that Infugen holds EU GMP certificates or has EDQM status.

Infugen Pharma Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's product registrations in various countries, including Nigeria, Tanzania, Kenya, Ghana, Uganda, the Philippines, Ethiopia, Zambia, Lesotho, Sri Lanka, the Democratic Republic of Congo, Vietnam, Ivory Coast, Cambodia, Portugal, Brazil, Tajikistan, and Yemen, reflect its adherence to international regulatory requirements. The company's export No Objection Certificates (NOCs) further demonstrate its compliance with Indian export regulations.

As of March 2026, there is no publicly available information indicating that Infugen Pharma Private Limited has received FDA Form 483 observations, warning letters, or import alerts. Similarly, there are no reports of regulatory actions from other authorities such as the WHO, EMA, MHRA, or TGA. The company's focus on obtaining WHO GMP certification for its oncology unit and product registrations in various countries suggests a proactive approach to regulatory compliance.

Infugen Pharma Private Limited operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly available, the company's focus on contract manufacturing services and its product portfolio, which includes tablets, capsules, IV infusions, antibiotics, and oncology drugs, position it as a significant player in the market. The company's WHO GMP certification for its oncology unit and product registrations in multiple countries enhance its competitive edge.

Infugen Pharma's key differentiators include its WHO GMP-certified oncology unit, which ensures high-quality manufacturing standards, and its extensive product portfolio of over 100 products available in more than 25 countries. The company's strategic focus on contract manufacturing services and its presence in diverse international markets further distinguish it from competitors.

Infugen Pharma's current strategic direction emphasizes contract manufacturing services, with a focus on pharmaceutical formulations and medical devices. The company's expansion into various international markets, including North and East Africa, French West Africa, Southeast Asia, Central America, the Caribbean, and CIS countries, reflects a strategy aimed at global growth and market diversification. The WHO GMP certification for its oncology unit underscores the company's commitment to meeting international quality standards, positioning it favorably for future growth opportunities.

Infugen Pharma Private Limited has demonstrated a strong track record in pharmaceutical manufacturing and export, with a product portfolio that includes tablets, capsules, IV infusions, antibiotics, and oncology drugs. The company's WHO GMP-certified oncology unit and product registrations in multiple countries indicate a commitment to quality and regulatory compliance. The company's focus on contract manufacturing services and its presence in diverse international markets further enhance its reliability as a supplier.

Importers should verify the following certifications when considering Infugen Pharma Private Limited as a supplier:

• WHO GMP Certification: To ensure compliance with international manufacturing standards.